Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Sanjay Popat

Professor of Thoracic Oncology

Institute of Cancer Research

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Pharmacology

40%

Pharmacotherapy

100%

Cancer Biology

80%

Targeted Therapy

70%

Oncology

70%

Tumor Suppressor

40%

Tyrosine Kinase

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles24

Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Article Link

Year:

2025

Durable Response to Lenvatinib in Platinum-Refractory Metastatic High-Grade Thymic Mucoepidermoid Carcinoma: A Case Report

Article Link

Year:

2025

Transportability of nonlocal real-world evidence and its relevance to health technology assessment: a primer

Article Link

Year:

2025

Mortality Outcomes in People with Lung Cancer with and without Type2 Diabetes: A Cohort Study in England

Article Link

Year:

2025

A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial

Article Link

Year:

2025

Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials

Article Link

Year:

2025

Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy

Article Link

Year:

2025

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Article Link

Year:

2025

Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?

Article Link

Year:

2024

Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family

Article Link

Year:

2024

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers

Article Link

Year:

2024

Inoperable stage III EGFR mutant non-small-cell lung cancer: time for drug first, local later?

Article Link

Year:

2024

RETaliation—Tackling Rare Resistance Alterations to Osimertinib

Article Link

Year:

2023

A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18F-Fluorothymidine “Flare” on Positron Emission Tomography

Article Link

Year:

2023

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Article Link

Year:

2023

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Article Link

Year:

2023

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

Article Link

Year:

2023

Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?

Article Link

Year:

2023

Response to letter entitled: Re: ‘Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib'

Article Link

Year:

2022

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L

Article Link

Year:

2022

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

Article Link

Year:

2022

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Article Link

Year:

2022

Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib

Article Link

Year:

2022

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

Article Link

Year:

2022

Collaborators8

Benjamin Besse

Université Paris-Saclay

FRANCE

Matthew Krebs

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

Joachim G. Aerts

NETHERLANDS

Yasushi YATABE

Chief

National Cancer Center Research Institute

JAPAN

Pilar Garrido López

Head Medical Oncology Department

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

SPAIN

Eric O. Aboagye

Imperial College London

UNITED KINGDOM

Anthonie van der Wekken

University of Groningen

NETHERLANDS

Jennifer Quint

Professor of Respiratory Epidemiology

Imperial College London

UNITED KINGDOM

How do I reach out?

Meet Kite AI